Nova Eye Medical Limited (ASX:EYE)
Australia flag Australia · Delayed Price · Currency is AUD
0.1350
-0.0025 (-1.82%)
Mar 18, 2026, 4:10 PM AEST

Nova Eye Medical Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Income
-7.03-9.06-8.79-15.29-7.5-4.36
Depreciation & Amortization
2.182.262.992.31.811.52
Other Amortization
0.04-----
Asset Writedown & Restructuring Costs
---6.04--
Stock-Based Compensation
0.090.090.040.180.2-
Other Operating Activities
0.381.09-0.13-0.24-1.63-0.18
Change in Accounts Receivable
-0.1-0.1-1.86-01.82-1.62
Change in Inventory
0.290.29-0.48-0.27-0.640.03
Change in Accounts Payable
-1.22-1.22-0.80.530.54-1.82
Change in Income Taxes
--0.880.69-0.16-8.15
Change in Other Net Operating Assets
0.50.50.280.210.011.43
Operating Cash Flow
-4.87-6.15-7.86-6.82-4.72-13.14
Capital Expenditures
-0.34-0.3-0.21-0.26-0.13-0.38
Cash Acquisitions
------0.99
Divestitures
----2.02-
Sale (Purchase) of Intangibles
-0.14-0.15-0.24-0.54-5.46-1.85
Other Investing Activities
0.070.090.120.1-0.970.24
Investing Cash Flow
-0.41-0.36-0.33-0.7-4.54-2.98
Long-Term Debt Repaid
--0.61-0.52-0.65-0.4-0.58
Net Debt Issued (Repaid)
-0.65-0.61-0.52-0.65-0.4-0.58
Issuance of Common Stock
6.176.177.437.47--
Repurchase of Common Stock
------41.64
Common Dividends Paid
------19.39
Financing Cash Flow
5.525.566.916.82-0.4-61.61
Foreign Exchange Rate Adjustments
0.12-0.1400.12-0.14-0.11
Net Cash Flow
0.37-1.1-1.27-0.58-9.8-77.85
Free Cash Flow
-5.21-6.45-8.07-7.09-4.85-13.53
Free Cash Flow Margin
-15.77%-22.03%-34.59%-41.63%-36.27%-100.99%
Free Cash Flow Per Share
-0.02-0.03-0.04-0.04-0.03-0.09
Cash Interest Paid
0.180.160.060.050.060.07
Cash Income Tax Paid
---0.88-1.4-1.428.85
Levered Free Cash Flow
-2.79-3.17-4.92-3-8.17-14.83
Unlevered Free Cash Flow
-2.67-3.07-4.88-2.96-8.13-14.79
Change in Working Capital
-0.53-0.53-1.970.192.39-10.12
Source: S&P Global Market Intelligence. Standard template. Financial Sources.